Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $82.2 million.

  • Agios Pharmaceuticals' Total Current Liabilities rose 129.38% to $82.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $82.2 million, marking a year-over-year increase of 129.38%. This contributed to the annual value of $82.2 million for FY2025, which is 129.38% up from last year.
  • As of Q4 2025, Agios Pharmaceuticals' Total Current Liabilities stood at $82.2 million, which was up 129.38% from $74.8 million recorded in Q3 2025.
  • Agios Pharmaceuticals' Total Current Liabilities' 5-year high stood at $119.5 million during Q3 2024, with a 5-year trough of $45.1 million in Q1 2023.
  • Moreover, its 5-year median value for Total Current Liabilities was $60.2 million (2021), whereas its average is $65.3 million.
  • In the last 5 years, Agios Pharmaceuticals' Total Current Liabilities plummeted by 5254.91% in 2022 and then surged by 10445.19% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Total Current Liabilities stood at $59.8 million in 2021, then rose by 4.69% to $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then rose by 19.43% to $81.2 million in 2024, then grew by 1.29% to $82.2 million in 2025.
  • Its Total Current Liabilities was $82.2 million in Q4 2025, compared to $74.8 million in Q3 2025 and $70.4 million in Q2 2025.